CSIMarket
 
Cvrx inc  (CVRX)
Other Ticker:  
 
 
Price: $20.8200 $-0.67 -3.118%
Day's High: $21.64 Week Perf: 0.68 %
Day's Low: $ 20.73 30 Day Perf: -9.2 %
Volume (M): 152 52 Wk High: $ 33.14
Volume (M$): $ 3,167 52 Wk Avg: $17.34
Open: $21.28 52 Wk Low: $8.38



 Market Capitalization (Millions $) 431
 Shares Outstanding (Millions) 21
 Employees -
 Revenues (TTM) (Millions $) 39
 Net Income (TTM) (Millions $) -41
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 1

Cvrx Inc
CvRx Inc. is a medical device company based in Minneapolis, Minnesota. It specializes in developing implantable technologies for the treatment of cardiovascular diseases. The company's main product is the BAROSTIM NEO System, which is an implantable device that delivers electrical signals to the baroreceptors in the carotid sinus. This therapy helps to regulate blood pressure and improve cardiac function in patients suffering from hypertension or heart failure. CvRx Inc. has gained recognition for its innovative approach to cardiovascular care and is dedicated to improving patient outcomes and quality of life.


   Company Address: 9201 West Broadway Avenue Minneapolis 55445 MN
   Company Phone Number: 416-2840   Stock Exchange / Ticker: NASDAQ CVRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Cvrx Inc

Cvrx Inc experiences impressive 70.805% surge in revenue during October-December 2023 period

CVRx Inc, a commercial-stage medical device company specializing in developing, manufacturing, and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, recently announced its financial and operating results for the fourth quarter and full year of 2023. The company also achieved FDA approval for expanded labeling of its Barostim therapy, marking a significant milestone in cardiac healthcare.
In terms of financial performance, CVRx Inc reported a shortfall per share of $-0.44 per share for the financial interval closing December 31, 2023. This represents an increase compared to $-0.26 per share in the previous year and a growth in shortfall from $-0.43 per share from the previous reporting season. However, it's worth noting that the company's revenue saw a strong increase of 70.805% to $12.26 million from $7.18 million in the corresponding reporting season a year ago. Sequentially, revenue improved by 24.817% from $9.82 million.

Product Service News

CVRx Secures FDA Approval for Expanded Labeling of Barostim, Bolstering U.S. Market Opportunity

Published Tue, Dec 26 2023 1:05 PM UTC

CVRx, a leading medical technology company, has recently attained FDA approval for expanded labeling of its innovative Barostim therapy. This development marks a significant milestone in the field of cardiac healthcare, as it not only amplifies the U.S. annual market prognosis but also underscores the efficacy of CVRx's long-term BeAT-HF data. With this regulatory nod, CVRx ...

Cvrx Inc

Cvrx Inc. Witnesses Exponential Revenue Growth and Significant Loss Reduction Throughout Q3 2023

Energetic Revenue Improvement for Cvrx Inc in Third Quarter of 2023
Cvrx Inc, a leading medical device company, has reported a remarkable revenue improvement in its third quarter of 2023. The company saw a surge of 67.978% to $9.82 million, which helped to reduce its losses to $-0.43 per share, from $-0.48 in the comparable reporting season a year prior. This performance stands out in comparison to its peers in the Medical Equipment & Supplies industry, as they have only experienced a 0.77% revenue improvement during the same period.
The improvement in revenue is a positive sign for Cvrx Inc, especially considering the previous quarter's growth of 9.318% from $8.98 million. Additionally, the company has made progress in improving its earnings per share, which increased to $-0.43 per share from $-0.56 in the previous quarter.

Cvrx Inc

Medical Equipment & Supplies Giant Cvrx Inc. Celebrates Stellar 78.553% Revenue Spike in Fiscal Year Ended June 2023



Cvrx Inc recently released their financial results for the fiscal time-frame ending June 30, 2023. These results reflect both positive and negative trends for the Medical Equipment & Supplies company. Let's delve into the key findings and explore how these developments might impact the company's future.
1. Increasing Deficit per Share:
In the reported period, Cvrx Inc saw a rise in their deficit per share, from $-0.49 to $-0.56, compared to the previous year's performance. The surge in deficit from the preceding reporting season further highlights the financial challenges faced by the company.

Cvrx Inc

Cvrx Inc Defies Financial Struggles with Swift Revenue Increase in Q1 2023

Cvrx Inc is a company that has been struggling financially in recent times. For the most recent fiscal period, the company increased its shortfall per share to $-0.55 per share, which is an increase from $-0.49 a year ago, and also an increase from $-0.26 per share from the prior financial reporting period. This indicates that the company's financial performance has been worsening.
However, the company's revenue has been growing strongly. In the most recent fiscal period, the revenue rose by 95.756 % to $7.98 million from $4.08 million in the corresponding financial reporting period a year ago. Also, sequentially, revenue advanced by 11.19 % from $7.18 million. Despite the growth in revenue, the company still recorded a net shortfall of $-11.374 million, which is larger than $-9.991 million a year ago.






 

Cvrx Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Cvrx Inc does not provide revenue guidance.

Earnings Outlook
Cvrx inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com